Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Adalimumab remains in newborn's bloodstream for at least three months

Adalimumab, a drug often prescribed for women with Crohn's disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn's bloodstream for at least three months, researchers at the University of California San Francisco have found.

9 May 2011

AGA honors four young gastroenterologists with prestigious Research Scholar Awards

The American Gastroenterological Association Research Foundation has announced its 2011 research scholars. The grants have been awarded to four outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

6 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

White youths less likely to be tested for STI in pediatric emergency department

When adolescent females visit a pediatric emergency department with complaints that may signal a sexually transmitted infection, white youths are less likely to be tested than blacks, according to a study to be presented Saturday, April 30, at the Pediatric Academic Societies annual meeting in Denver.

30 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

Researchers reveal how immune system distinguishes between beneficial and pathogenic organisms

The human gut is filled with 100 trillion symbiotic bacteria-ten times more microbial cells than our own cells-representing close to one thousand different species. "And yet, if you were to eat a piece of chicken with just a few Salmonella, your immune system would mount a potent inflammatory response," says Sarkis K. Mazmanian, assistant professor of biology at the California Institute of Technology (Caltech).

22 Apr 2011

IBD patients at greater risk of death if infected with Clostridium difficile

Patients admitted to hospital with inflammatory bowel disease (IBD) face a sixfold greater risk of death if they become infected with Clostridium difficile, a new study has found. The researchers say IBD patients should be screened on admission to protect them from serious illness.

20 Apr 2011

Scientist discovers new molecular mechanism underlying asthma, COPD

Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease and several other lung conditions.

18 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.

15 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Experts to discuss latest findings in IBD research at Rome meeting

Experts from 11 countries will gather this week in Rome to discuss innovative strategies for studying and treating Inflammatory Bowel Diseases.

12 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture biologic drugs

PharmaPraxis, from Axis Biotec, Cryopraxis, Silvestre Labs and CellPraxis Group, announces the formalization of an agreement with Brazil's Ministry of Health to manufacture biologic drugs.

7 Apr 2011

New discovery on IL-23 can lead to novel IBD treatments

A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.

1 Apr 2011

Insight into bowel cancer

Stem cells in the intestine, which when they mutate can lead to bowel cancers, might also be grown into transplant tissues to combat the effects of those same cancers, the UK National Stem Cell Network annual science meeting will hear today.

31 Mar 2011

Nycomed submits teduglutide MAA to EMA for SBS treatment

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported that Nycomed, a global pharmaceutical company, headquartered in Switzerland, has submitted a Marketing Authorization Application to the European Medicines Agency for clearance to market teduglutide as a once-daily subcutaneous treatment for short bowel syndrome.

29 Mar 2011

Inflammatory bowel disease in children - Delays in diagnosis common

Once a medical rarity in children, inflammatory bowel disease today is increasingly common in kids, but many of them may not be diagnosed in a timely manner, according to experts from the Pediatric Inflammatory Bowel Disease Center at Johns Hopkins Children’s Center.

28 Mar 2011